| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Rebaudioside O (Reb O) functions primarily as a sweetener by interacting with sweet taste receptors on the tongue. It binds to the T1R2/T1R3 receptor complex, a class 1 G protein-coupled receptor heterodimer, triggering a signal transduction pathway that leads to the perception of sweetness . Additionally, Reb O is categorized under "Other Targets" in pharmacological classification, with its primary application being as a sweetening agent rather than a therapeutic agent targeting specific disease-related pathways
|
|---|---|
| ln Vitro |
The compound is primarily characterized by its physicochemical properties. It is soluble in DMSO at concentrations of 50 mg/mL (34.78 mM) . As a steviol glycoside, Reb O is expected to be metabolized by gut microflora rather than by liver enzymes, similar to other steviol glycosides, but specific in vitro metabolic studies are not detailed.
|
| References |
|
| Additional Infomation |
Rebaudioside O (Reb O) is a minor steviol glycoside naturally present in trace amounts in Stevia rebaudiana leaves . It has the CAS number 1220616-48-7, a molecular weight of 1437.44 g/mol, and a purity specification of ≥95% (typically >98% by HPLC) . Reb O is often used in combination with other steviol glycosides such as rebaudioside D, rebaudioside M, rebaudioside A, rebaudioside N, and rebaudioside E to achieve improved sensory properties in zero-calorie beverages . In optimized steviol glycoside compositions, Reb O typically accounts for about 0.5% to 5% of the total steviol glycoside content, and together with rebaudiosides A, N, and E, accounts for 1.7% to 14% of the total content . The compound is soluble in DMSO (≥50 mg/mL) and is typically stored as a white to off-white solid powder at -20°C, protected from light . LogP is -7.1, indicating high hydrophilicity . The compound is covered in patent applications related to steviol glycoside sweetener compositions with improved flavor profiles (WO2017059414A1/EP3355720B1) .
|
| Molecular Formula |
C62H100O37
|
|---|---|
| Molecular Weight |
1437.43522453308
|
| Exact Mass |
1436.594
|
| CAS # |
1220616-48-7
|
| PubChem CID |
92023639
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Leguminosae Cassia
Originated from plants: Compositae |
| LogP |
-7.1
|
| Hydrogen Bond Donor Count |
22
|
| Hydrogen Bond Acceptor Count |
37
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
99
|
| Complexity |
2710
|
| Defined Atom Stereocenter Count |
41
|
| SMILES |
O([C@H]1C(C(C(C(CO)O1)O)O[C@H]1C(C(C(C(CO)O1)O)O)O)O[C@H]1C(C(C(C(CO)O1)O)O)O)[C@@]12C(=C)C[C@]3(CC[C@H]4[C@@](C(=O)OC5C(C(C(C(CO)O5)O)O[C@H]5C(C(C(C(CO)O5)O)O)O)O[C@H]5C(C(C(C(C)O5)O)O[C@H]5C(C(C(C(CO)O5)O)O)O)O)(C)CCC[C@@]4(C)[C@@H]3CC1)C2
|
| InChi Key |
KTOQMKFUTRIEQB-GXSUQLSCSA-N
|
| InChi Code |
InChI=1S/C62H100O37/c1-20-12-61-10-6-28-59(3,29(61)7-11-62(20,19-61)99-57-50(97-54-44(83)40(79)34(73)25(16-66)90-54)48(36(75)27(18-68)92-57)95-53-43(82)39(78)33(72)24(15-65)89-53)8-5-9-60(28,4)58(85)98-56-49(47(35(74)26(17-67)91-56)94-52-42(81)38(77)32(71)23(14-64)88-52)96-55-45(84)46(30(69)21(2)86-55)93-51-41(80)37(76)31(70)22(13-63)87-51/h21-57,63-84H,1,5-19H2,2-4H3/t21-,22+,23+,24+,25+,26+,27+,28-,29-,30-,31+,32+,33+,34+,35+,36+,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,47-,48-,49+,50+,51-,52-,53-,54-,55-,56-,57-,59+,60+,61+,62-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5R,6R)-3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| Synonyms |
REBAUDIOSIDE O; 1220616-48-7; RefChem:178705; ((2S,3R,4S,5R,6R)-3-((2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxyoxan-2-yl)oxy-5-hydroxy-6-(hydroxymethyl)-4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxyoxan-2-yl) (1R,4S,5R,9S,10R,13S)-13-((2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy)oxan-2-yl)oxy-5,9-dimethyl-14-methylidenetetracyclo(11.2.1.01,10.04,9)hexadecane-5-carboxylate; [(2S,3R,4S,5R,6R)-3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~34.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (0.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (0.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (0.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6957 mL | 3.4784 mL | 6.9568 mL | |
| 5 mM | 0.1391 mL | 0.6957 mL | 1.3914 mL | |
| 10 mM | 0.0696 mL | 0.3478 mL | 0.6957 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
